Xlife Sciences AG (XSWX:XLS) Debt-to-Asset : 0.12 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF17.25
GF Value CHF7.20
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Debt-to-Asset?

Xlife Sciences AG XSWX:XLS -1.99% 53 Debt-to-Asset is 0.12 as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.20 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was CHF6.64 Mil. Xlife Sciences AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was CHF53.37 Mil. Xlife Sciences AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was CHF517.12 Mil. Xlife Sciences AG's debt to asset for the quarter that ended in Dec. 2025 was 0.12.

Xlife Sciences AG  (XSWX:XLS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Xlife Sciences AG Debt-to-Asset Related Terms

Xlife Sciences AG Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Debt-to-Asset Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.13 0.12 0.11 0.11 0.12

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.11 0.11 0.11 0.12

XSWX:XLS vs VRTX, REGN, ALNY: Debt-to-Asset Comparison

For the Biotechnology subindustry, Xlife Sciences AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xlife Sciences AG Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Debt-to-Asset falls into.


XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Xlife Sciences AG's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.636 + 53.366) / 517.117
=0.12

Xlife Sciences AG's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.636 + 53.366) / 517.117
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.12 mean?
Xlife Sciences AG (XSWX:XLS) has a Debt-to-Asset of 0.12 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Debt-to-Asset too high?
Xlife Sciences AG's current Debt-to-Asset is 0.12. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Debt-to-Asset compare to VRTX and REGN?
Xlife Sciences AG's Debt-to-Asset of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Debt-to-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.20, compared to a current price of CHF17.25 — trading 139.6% above its estimated fair value. The current Debt-to-Asset is 0.12. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Debt-to-Asset is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF17.25 is trading 139.6% above its estimated GF Value™ of CHF7.20. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Debt-to-Asset: 0.12
  • GF Value™: CHF7.20 vs. price of CHF17.25 (139.6% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF17.25
Price
CHF7.20
GF Value